These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 5691554)

  • 21. Development of extremely attenuated live measles virus vaccine (CAM-EX).
    Ueda S; Takahashi M; Kurimura T; Minekawa Y; Suzuki N
    Biken J; 1972 Sep; 15(3):173-7. PubMed ID: 4643692
    [No Abstract]   [Full Text] [Related]  

  • 22. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
    Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
    J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative results of anti-measles serological immunity after the disease and after vaccination].
    Topciu V; Moldovan E; Csaky N; Băcilă E
    Arch Roum Pathol Exp Microbiol; 1970 Dec; 29(4):671-5. PubMed ID: 5521121
    [No Abstract]   [Full Text] [Related]  

  • 24. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
    Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
    Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measles vaccine reactions in a virgin population.
    Black FL; Woodall JP; Pinheiro FD
    Am J Epidemiol; 1969 Feb; 89(2):168-75. PubMed ID: 5765956
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical and immunoserological study of vaccine and spontaneous measles].
    Yoneda Y
    Nihon Shonika Gakkai Zasshi; 1967 Nov; 71(11):1406-16. PubMed ID: 5628247
    [No Abstract]   [Full Text] [Related]  

  • 27. [Study on the long-term observation of measles vaccine immunity. 1. End results of vaccination and re-vaccination].
    Tsukada Y
    Nihon Shonika Gakkai Zasshi; 1968 Apr; 72(4):473-87. PubMed ID: 5692409
    [No Abstract]   [Full Text] [Related]  

  • 28. [Evaluation of the vaccination of a misture of inactivated and live measles vaccines. 1. Clinicoserological observation for a period of 4 years].
    Tanaka H
    Nihon Shonika Gakkai Zasshi; 1972 Mar; 76(3):162-9. PubMed ID: 5065657
    [No Abstract]   [Full Text] [Related]  

  • 29. [Rubeola vaccination. Serological and clinical studies of the "Cendehill strain" live vaccine].
    Zellweger U; Kayser FH; Hitzig WH
    Dtsch Med Wochenschr; 1969 Mar; 94(10):461-5. PubMed ID: 5764887
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative studies of measles vaccines in a controlled trial in the USSR.
    Bolotovskij VM; Nefedova LA; Gelikman BG; Zargaryants AT; Zetilova LP; Nastasina KT
    Bull World Health Organ; 1966; 34(6):859-64. PubMed ID: 5296534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination.
    Dilraj A; Sukhoo R; Cutts FT; Bennett JV
    Vaccine; 2007 May; 25(21):4170-4. PubMed ID: 17408818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Inoculation of highly attenuated measles vaccine].
    Shian R
    Nihon Shonika Gakkai Zasshi; 1969 Oct; 73(10):1751-9. PubMed ID: 5390808
    [No Abstract]   [Full Text] [Related]  

  • 33. [Epidemiological analysis of cases with rash and fever illness after measles vaccine inoculation during 1999 to 2002 in Shandong province, China].
    Xu AQ; Xu Q; Song LZ; Xiao ZK; Zhang L; Wang CY; Wang TZ; Li RP; Li MS; Li Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):417-20. PubMed ID: 15231169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical laboratory experiences with a more attenuated Enders' measles virus vaccine (Moraten) combined with smallpox vaccine.
    Weibel RE; Stokes J; Buynak EB; Leagus MB; Hilleman MR
    Pediatrics; 1969 Apr; 43(4):567-72. PubMed ID: 4304934
    [No Abstract]   [Full Text] [Related]  

  • 35. Unusual clinical reactions to live measles vaccine in a child previously immunized with killed measles vaccine.
    Iwai T; Matumoto M; Kawana R
    Jpn J Exp Med; 1968 Apr; 38(2):139-42. PubMed ID: 5304930
    [No Abstract]   [Full Text] [Related]  

  • 36. [Persistence of antibodies after vaccination against measles (author's transl)].
    Sejda J; Strauss J; Pecenka J; Strnad P
    Cesk Epidemiol Mikrobiol Imunol; 1977 Mar; 26(2):76-82. PubMed ID: 141341
    [No Abstract]   [Full Text] [Related]  

  • 37. Live measles vaccine prepared in dog kidney cells. 3. Vaccination against measles with Czechoslovak live vaccine.
    Adam E; Kratochvílova M; Mares I; Drevo M; Závadová H
    J Hyg Epidemiol Microbiol Immunol; 1966; 10(2):232-9. PubMed ID: 5330077
    [No Abstract]   [Full Text] [Related]  

  • 38. [Study on the subclinical infection of the recipients of measles vaccine].
    Wu T; Wang SL; Xiang YZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 1996 Apr; 17(2):70-2. PubMed ID: 8758397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody titres and protective efficacy two to four years after vaccination against measles.
    Watson GI; Parry JM
    Mon Bull Minist Health Public Health Lab Serv; 1967 Aug; 26():146-53. PubMed ID: 5630480
    [No Abstract]   [Full Text] [Related]  

  • 40. A study of the protective effect of live measles vaccines 13 to 27 months after vaccination.
    Sejda J; Helcl J; Strauss J; Zdrazílek J; Mírovský J
    J Hyg Epidemiol Microbiol Immunol; 1968; 12(2):187-91. PubMed ID: 5752748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.